Taurine Decreases Fecal Fatty Acid and Sterol Excretion in Cystic Fibrosis: A Randomized Double-blind Trial

Lesley J. Smith, Florence Lacaille, Guy Lepage, Nancy Ronco, André Lamarre, Claude C. Roy

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Patients with cystic fibrosis may still have a significant degree of steatorrhea despite adequate pancreatic enzyme supplementation. Taurine is a conditionally essential amino acid that possibly improves the micellar phase of fat digestion. Thirteen children with cystic fibrosis and a significant degree of steatorrhea (>13 g/d) were enrolled in a randomized double-blind crossover study of taurine (30 mg/kg per day) in contrast to placebo for two successive 4-month periods. No difference was noted in height and weight velocity, lung function, vitamin A level, and essential fatty acid status. Twelve of the 13 patients showed a decrease in fecal fatty acid excretion (26.5±2.6 g/24 h vs 15.4±2.5 g/24 h), affecting mainly saturates and monounsaturates, and a decrease in total sterol excretion (1492.6±303 mg/24 h vs 1211.7±213.8 mg/24 h) while ingesting taurine. Taurine may be a useful adjunct in patients with cystic fibrosis and severe steatorrhea.

Original languageEnglish (US)
Pages (from-to)1401-1404
Number of pages4
JournalAmerican Journal of Diseases of Children
Volume145
Issue number12
DOIs
StatePublished - Dec 1991

    Fingerprint

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this